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Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing significant morbidity and
mortality. No vaccine or specific, effective treatment is currently available. A more complete understanding of the key components
of effective host response to RSVand novel preventative and therapeutic interventions are urgently required. Cathelicidins are host
defense peptides, expressed in the inflamed lung, with key microbicidal and modulatory roles in innate host defense against infec-
tion. In this article, we demonstrate that the human cathelicidin LL-37 mediates an antiviral effect on RSV by inducing direct
damage to the viral envelope, disrupting viral particles and decreasing virus binding to, and infection of, human epithelial cells
in vitro. In addition, exogenously applied LL-37 is protective against RSV-mediated disease in vivo, in a murine model of pulmonary
RSV infection, demonstrating maximal efficacy when applied concomitantly with virus. Furthermore, endogenous murine cath-
elicidin, induced by infection, has a fundamental role in protection against disease in vivo postinfection with RSV. Finally, higher
nasal levels of LL-37 are associated with protection in a healthy human adult RSV infection model. These data lead us to propose
that cathelicidins are a key, nonredundant component of host defense against pulmonary infection with RSV, functioning as a first
point of contact antiviral shield and having additional later-phase roles in minimizing the severity of disease outcome. Consequently,
cathelicidins represent an inducible target for preventative strategies against RSV infection and may inform the design of novel
therapeutic analogs for use in established infection. The Journal of Immunology, 2016, 196: 2699–2710.
R
espiratory syncytial virus (RSV) is an important pathogen
of the human respiratory tract (1). RSV infection results
in viral bronchiolitis in ∼30% of infants who become
infected, and it can result in life-threatening severe bronchiolitis
and viral pneumonia in ∼2% of all infants (2). RSV causes sig-
nificant mortality in the developing world, resulting in an esti-
mated 200,000 annual deaths in young children globally, in
addition to major morbidity (33.8 million episodes worldwide
annually) (3). Although the majority of children recover after only
mild symptoms, children experiencing severe or recurrent bron-
chiolitis have an increased risk for recurrent wheeze and asthma
(4, 5). The variability in susceptibility to RSV-induced disease and
outcomes is not understood and is proposed to have host- and
virus-specific causes, as well as showing seasonal variation. In
addition, apart from costly passive immunization, which is re-
served for very high risk infants, there is no vaccine or effective
specific treatment available for RSV bronchiolitis, other than
supportive measures (6). Therefore, a clearer understanding of
components of host defense that contribute to effective protection
against RSV infection and disease is urgently required and could
inform the development of novel preventative or therapeutic
strategies.
We have previously demonstrated that the human cathelicidin
LL-37 has dose-dependent antiviral activity against RSV in vitro
(7). Cathelicidins are a family of host defense peptides (also
known as antimicrobial peptides), with key functions in the in-
nate immune system, having both direct microbicidal and mul-
tiple host defense modulatory functions (reviewed in Ref. 8).
These peptides are expressed over a broad range of sites in in-
fection and inflammation, generated primarily by neutrophils
and epithelial cells (reviewed in Refs. 9, 10). Humans and mice
each encode only one cathelicidin; the human cationic antimi-
crobial peptide of 18 kDa (hCAP-18) is the sole human cath-
elicidin, encoded by the CAMP gene (11, 12), and the murine
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ortholog mCRAMP is encoded by the murine Camp gene (13).
LL-37, the main active form of human cathelicidin, is generated
proteolytically from hCAP-18 (14), can be detected in a wide
range of body fluids, including airway surface liquid, and is
upregulated by infection and inflammation (8). Our previous
work has indicated that cathelicidin may represent an important
targetable component of innate host defense against RSV in-
fection (7). However, the mechanism of action of this peptide-
mediated antiviral activity, the in vivo potential of exogenously
applied cathelicidins, and the physiological significance of en-
dogenous respiratory tract expression of cathelicidin in RSV
infection and disease remained unknown.
In this article, we demonstrate that LL-37 mediates an anti-
viral effect on RSV via direct damage to the viral envelope,
disrupting viral particles and decreasing virus binding to, and
infection of, epithelial cells. This activity results in protection
against RSV infection and disease in a murine model of pul-
monary RSV infection, demonstrating maximal efficacy when
LL-37 is applied concomitantly with virus. In addition, murine
cathelicidin, mCRAMP, also has antiviral activity against RSV
in vitro, is induced in the lungs in response to RSV, and con-
tributes to protection against disease postinfection with RSV.
Finally, higher nasal levels of LL-37 are associated with pro-
tection against infection in a healthy human adult RSV infection
model.
Materials and Methods
Ethics statement
Mouse experiments were performed in accordance with Home Office UK
project license 60/4216, under the Animal (Scientific Procedures) Act 1986.
For human studies, a cohort of healthy nonsmoking adults (aged 18–33 y;
with no underlying immunodeficiencies) was enrolled, providing written
informed consent, approved by the UK National Research Ethics Service
West London Research Ethics Committee (study numbers 10/H0711/94
and 11/LO/1826) and the Imperial College Joint Research Office.
Peptide synthesis
LL-37, scrambled LL-37 (scrLL-37), and mCRAMP peptides were custom
synthesized by Almac (East Lothian, U.K.) using Fmoc solid-phase syn-
thesis and reversed phase HPLC purification. Peptide identity was con-
firmed by electrospray mass spectrometry, purity (.95% area) by reversed
phase HPLC, and net peptide content determined by amino acid analysis.
Lyophilized peptides were reconstituted in endotoxin-free water at 5 mg/ml
stock concentration and determined to be endotoxin-free using a Limulus
Amebocyte Lysate Chromogenic Endotoxin Quantitation Kit (Thermo
Scientific). Peptide functionality was confirmed by assessing antiendotoxic
activity (15).
Cell culture
HEp-2 cells (ATCC CCL-23) were cultured in DMEM/F12 (Life
Technologies/Life Technologies, Paisley, U.K.), supplemented with 2 mM
L-glutamine (PAA Laboratories, Yeovil, U.K.) and 10% FCS (Biosera, East
Sussex, U.K.), at 37˚C and 5% CO2.
Virus propagation and purification
RSV strain A2 was purchased from American Type Culture Collection
(ATCC-VR1540). Virus was propagated by infecting 70% confluent HEp-2
cells with a multiplicity of infection (MOI) of 0.1 for 2 h in 6 ml serum-free
DMEM-F12, after which 20 ml medium containing 10% FCS (PAA
Laboratories) was added and cells were cultured for 24 h. FCS content was
reduced to 2% and virus was harvested at 70% cytopathic effects. Su-
pernatant was clarified by centrifugation, snap-frozen, and stored at280˚C.
For sucrose purification, clarified supernatant was centrifuged through a
7.5-ml 30% (w/v) sucrose cushion (24,000 rpm, 2 h, 4˚C, Beckman XI-90
ultracentrifuge, SW28 rotor), with brake set to minimum. Virus pellets
obtained from each 175-cm2 cell culture flask were resuspended in 200 ml
serum-free DMEM-F12. For envelope-preserving inactivation, sucrose-
purified RSV-A2 was treated with 10 mM Aldrithiol (Sigma-Aldrich,
Dorset, U.K.) for 24 h, 4˚C, and was snap-frozen and stored at 280˚C.
LL-37 solid-phase ELISA
High-affinity binding plates [High bind microplate (Costar Corning,
Tewksbury, MA) 3590 were coated with 1 3 106 PFU RSV in coating
buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6)], control cell culture
medium, or 2.5% BSA for 12 h at 4˚C, washed with PBS, and incubated
with 2.5% BSA for 3 h. Wells were exposed to 2 mg/ml LL-37 for 30 min
at 4˚C, washed with 0.02% Tween 20/PBS. Bound LL-37 was detected by
anti–LL-37 Ab (1:6400, G-075-06; Phoenix Pharmaceuticals, Burlingame,
CA), HRP-labeled secondary Ab [1:5000, goat anti-rabbit IgG (H+L)
(Jackson Laboratories, West Grove, PA), 111-035-045], and TMB sub-
strate. Reaction was stopped using 0.5 M sulfuric acid, and absorbance at
A450 was determined using a plate reader (Synergy HT; Biotek, Winooski,
VT).
RSV solid-phase ELISA
High-affinity binding plates were coated with 2 mg/ml LL-37 or scrLL-37
for 12 h at 4˚C, washed with PBS, and incubated with 2.5% BSA for 3 h.
RSV 3.253 105 PFU was added for 30 min at 4˚C, and wells were washed
with 0.02% Tween 20/PBS. For detection of bound RSV, wells were ex-
posed to anti-RSV Ab (1:200; Goat Anti Respiratory Syncytial Virus Bi-
otin Polyclonal 7950-0104; AbD Serotec, Kidlington, U.K.), HRP-labeled
secondary Ab (1:10,000, P0449; Dako, Glostrup, Denmark), and TMB
substrate (Bio-Rad). Reaction was stopped using 0.5 M sulfuric acid, and
absorbance at A450 was determined using a plate reader (Synergy HT;
Biotek, Winooski, VT).
Immunofluorescence staining for N/F-protein colocalization by
confocal microscopy
As described by Krzyzaniak et al. (16), 5 3 102 PFU RSV was exposed to
25 mg/ml LL-37, scrLL-37, or endotoxin-free water, immediately air-dried
on glass slides and fixed (10% neutral buffered formalin; Sigma-Aldrich).
Particles were permeabilized with 0.2% Triton X-100 (Sigma-Aldrich) and
incubated 1% BSA in TBST (1 h, 4˚C; Sigma-Aldrich). F- and N-protein
were detected using primary Abs [1:100 Anti-Respiratory Syncytial Virus
Ab (2F7), ab43812 (Abcam, Cambridge, U.K.), and Anti-RSV Ab, nu-
cleoprotein, clone 130-12H, MAB858-3 (Millipore, Darmstadt, Germany)
respectively], followed by Alexa Fluor–labeled secondary Abs [1:50,
Alexa Fluor 488 Goat-anti mouse IgG2a (y2a), Alexa Fluor594 Goat-anti
mouse IgG1 (Y1); Life Technologies]. Samples were embedded in Pro-
Long Diamond Antifade reagent (Life Technologies). Slides were viewed
with a Leica SP confocal microscope (original magnification 3100),
collecting 10 images per treatment condition. Colocalization was analyzed
using IMARIS software (Bitplane, Zurich, Switzerland), with thresholds
set to include particles .0.05 mm and signal quality higher than 15, and
particles were counted using ImageJ.
Transmission electron cryomicroscopy
A total of 43 104 PFUAldrithiol-inactivated RSV was exposed to 25 mg/ml
LL-37 or endotoxin-free water. Then, 4 ml pretreated RSV was applied to
freshly glow-discharged Quantifoil-grids (R2/2, 400 mesh; Quantifoil,
Großlo¨bichau, Germany) and vitrified with a FEI Vitrobot IV (FEI,
Hillsboro, OR) at 100% humidity and 4˚C (blot force 10, blot time 2 s).
Vitrified samples were transferred with a Gatan 626 cryoholder into a FEI-
F20 electron microscope operated at 200 kV. Micrographs were semiau-
tomatically acquired with EM-tools (TVIPS) on an 8kx8k CMOS detector
(Tvips F816) at a nominal original magnification 350,000 (calibrated
pixel size, 1.53 A˚/Px) and with an approximate dose of 20 e2/A˚2.
Assessment of IFN-b, IL-28, and IL-29 expression by
quantitative RT-PCR
HEp-2 cells were infected with RSV (MOI = 1) for 2 h, inoculum was
replaced by fresh medium, and infection continued for 24 h. Cells were
lysed and RNA was isolated using the Qiagen RNeasy mini kit (Man-
chester, U.K.) according to manufacturer’s instructions. cDNA was gen-
erated by means of quantitative RT-PCR (Q-RT-PCR) using the TaqMan
Reverse Transcription Reagents (Applied Biosystems, Bleiswijk, the
Netherlands) according to manufacturer’s instructions (25˚C: 10 min,
48˚C: 40 min, 95˚C: 5 min, 4˚C: hold). TaqMan-based Q-RT-PCR was
performed for human IFN-b (Life Technologies, Paisley, U.K.) and
human IL-28 and IL-29 (sequences kindly provided by Dr. Michael
Edwards, Imperial College London). VIC-labeled 18S primer/probe mix
(Applied Biosystems) was used as endogenous control. Samples were run on
an ABI Prism 7900HT Real-Time PCR System. The primer sequences used
included: human IL-28AB: forward, 59-CTGCCACATAGCCCAGTTCA-39;
reverse, 59-AGAAGCGACTCTTCTAAGGCATCTT-39; probe, 59-TCTCCA-
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CAGGAGCTGCAGGCCTTTA-39; human IL-29: forward, 59 GGACGCC-
TTGGAAGAGTCACT-39; and reverse: 59-AGAAGCCTCAGGTCCCAA-
TTC-39; probe, 59-AGTTGCAGCTCTCCTGTCTTCCCCG-39.
Quantification of RSV binding by flow cytometry and Western
blotting
Following a protocol adapted from Krzyzaniak et al. (16), HEp-2 cells
were detached using versene solution (Sigma Aldrich), washed, exposed to
25 mg/ml LL-37, scrLL-37, or endotoxin-free water, and chilled on ice for
30 min. Cells were washed and exposed to RSV (MOI = 1) concomitant
with 25 mg/ml LL-37, scrLL-37, or endotoxin-free water for 1 h at 4˚C.
For flow cytometry, cells were washed, fixed (4% paraformaldehyde;
Sigma-Aldrich), resuspended in anti–F-protein Ab [1:200, Anti-Respiratory
Syncytial Virus Ab (2F7), ab43812; Abcam] for 12 h at 4˚C, and stained
with AF488-labeled secondary Ab [1:200, Alexa Fluor 488 goat
anti-mouse IgG2a (y2a); Life Technologies]. Samples were run on the
FACSCalibur (BD Biosciences, Oxford, U.K.) using Cell Quest (BD
Biosciences) V3.2.1 within 1 h, and results were analyzed using FlowJo
(FlowJo, Ashland, OR).
For Western blotting, RSV-exposed cells were washed, taken up in
sample buffer and reducing agent (Invitrogen, Paisley, U.K.), and
incubated at 95˚C for 10 min. SDS-PAGE on 10% Bis/Tris gels in MES
buffer (Invitrogen) was performed, protein was transferred to nitrocel-
lulose membranes, which were exposed to anti–F-protein Ab (1:200, Anti-
Respiratory Syncytial Virus Ab [2F7], ab43812; Abcam), followed by
HRP-labeled secondary Ab (goat anti-mouse, 115-035-062; Jackson Lab-
oratories). Chemiluminescence (Amersham ECL Prime Western Blotting
Detection Reagent; GE Healthcare, Little Chalfont, U.K.) was detected by
x-ray film, and band density was quantified using ImageJ.
In vitro antiviral activity of mCRAMP by immunoplaque assay
Confluent HEp-2 cells were infected with RSV (MOI = 0.005) concomitant
with 1, 10, 25, and 50 mg/ml mCRAMP, 25 mg/ml LL-37, or endotoxin-free
water for 2 h at 37˚C. Inoculum was removed, infection was continued for
24 h at 37˚C, and cells were fixed (2% hydrogen peroxide in methanol).
Cells were exposed to biotinylated anti-RSV Ab (1:200, Goat Anti Re-
spiratory Syncytial Virus Biotin Polyclonal, 7950-0104; AbD Serotec,
Oxford, U.K.), washed, incubated with ExtrAvidin peroxidase (1:500;
Sigma), and washed again. 3-Amino-ethylcarbazole substrate was used
according to manufacturer’s instructions (Sigma-Aldrich). Positive immu-
noplaques were quantified by light microscopy.
Infection and peptide treatments of mice
For experiments using wild-type mice, female BALB/c mice were supplied
by Charles River Laboratories (Tranent, U.K.), maintained with littermates
in local specified pathogen-free facilities in individually ventilated cages
for at least 1 wk before experimental use at 6–8 wk of age. Mice were
randomly allocated into infection or control cages with matched litter-
mates. Within each cage, mice were randomly allocated to different
treatment groups (LL-37 or scrLL-37, and/or varied timing of peptide
delivery dependent upon the study), with only one mouse per condition per
cage, the mouse being the experimental unit and repeated experimental
blocks conducted on different days. Mice received 100 ml RSV (5.6 3 105
PFU) or PBS by intranasal delivery under light general anesthesia (iso-
flurane). A total of 10 mg/mouse LL-37 or scrLL-37 (given as 100 ml of
100 mg/ml solution) was either given 1 h before infection, or coadminis-
tered or given 1 h postinfection. Mice further received a daily dose of 10
mg/mouse LL-37 or scrLL-37 until day 6 postinfection. Body weights were
monitored daily, and groups of mice were culled on day 4 or 7 postin-
fection. For studies using cathelicidin-deficient mice, wild type C57BL/6J
OlaHsd and Camp2/2 mice (17), backcrossed to congenicity into C57BL/6J
OlaHsd strain in-house, were bred from homozygous matings in-house in
specified pathogen-free facilities, in individually ventilated cages. Female
sister pairs of both genotypes (8–12 wk) were randomly partnered and
cohoused as one wild-type and one Camp2/2 mouse per cage, with the
pair of cages allocated as one infected and one control. Mice received 2.3–
5.6 3 105 PFU RSV or PBS by intranasal delivery under light general an-
esthesia (isoflurane), body weights were monitored daily, and mice were
culled on days 4 and 6 postinfection. Lungs were removed and processed
as described later.
Assessment of mCRAMP protein expression by Western
blotting
Lung tissue was homogenized [Precellys CK14 (Kit ceramic, 1.4 mm, 2-ml
tubes, 432-3751, settings 5000-2x50, Precellys24 tissue homogenizer;
Bertin Technologies] in MPer (Thermo Fisher Scientific, Paisley, U.K.),
lysed under constant agitation (4˚C, 20 min), and supernatant collected.
Protein content of lysed tissue supernatant was determined using a
bicinchoninic acid assay (Pierce BCA Protein Assay Kit; Thermo Sci-
entific), according to manufacturer’s instructions, to enable equivalent
loading. Samples were incubated at 95˚C for 10 min in sample buffer and
reducing agent [NuPAGE LDS Sample buffer (43) and NuPAGE Sample
Reducing Agent (103); Invitrogen]. SDS-PAGE on 4–12% Bis/Tris gels
in MES buffer (Invitrogen) was performed, protein was transferred to
nitrocellulose (Nitrocellulose Membrane Filter paper, Sandwich, 0.2-mm
pore size; Life Technologies), and membranes were exposed to anti-
mCRAMP Ab (1:500, CRAMP Ab, PA-CPPL-100; Innovagen AB,
Lund, Sweden) and anti–b-actin Ab (1:20000, clone AC-15; Sigma-
Aldrich), followed by the respective IRDye680LT or 800CW Li-Cor
labeled secondary Ab (Li-Cor Biotechnology, Cambridge, U.K.). Fluo-
rescence intensity was quantified using a Li-Cor Biosciences Odyssey
9120 Infrared Imaging System.
Assessment of Camp transcription and viral load by Q-RT-PCR
Lung tissue was homogenized in cell lysis buffer (20 mM Hepes, 0.3 mM
NaCl, 1.5 mM, MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM orthovanadate,
0.5% Triton X-100, Complete Protease Inhibitor Cocktail Tablets; Roche
Diagnostics, Basel, Switzerland), supernatant was isolated, and RNAwas
prepared using the Qiagen RNeasy mini kit according to manufacturer’s
instructions. cDNA was generated using TaqMan Reverse Transcription
Reagents (Applied Biosystems) according to manufacturer’s instructions
(25˚C: 10 min, 48˚C: 40 min, 95˚C: 5 min, 4˚C: hold). Q-RT-PCR
FIGURE 1. LL-37 binds directly to RSV. LL-37 (A) and RSV (B) solid-
phase ELISAs were performed by coating high-affinity binding plates with
BSA, RSV, or cell culture medium (A) or BSA, LL-37, or scrLL-37 (B).
Plates were incubated with LL-37 (A) or RSV (B), and were either exposed
to anti–LL-37 or anti-RSV Ab, followed by HRP-labeled secondary Abs
and detection with TMB. Data show mean absorbance at 450 nm from n =
3 independent experiments, each performed in triplicate, and analyzed by
one-way ANOVA with Dunnett posttest (*p , 0.05, **p , 0.01, ***p ,
0.001).
The Journal of Immunology 2701
(TaqMan Gene Expression Master Mix; Applied Biosystems) for RSV
L-gene was performed on an ABI Prism 7900HT Real-Time PCR System,
either using a commercial primer/probe set [murine, Mm00438285_m1,
TaqMan (Applied Biosystems); VIC-labeled 18S primer/probe mix was
used as an endogenous control], or using the following primers and
probe set: RSV L gene: Fwd, 59-GAACTCAGTGTAGGTAGAATGTT-
TGCA-39; Rev, 592TTTCAGCTATCATTTTCTCTGCCAAT-39; probe,
592TTTGAACCTGTCTGAACATTCCCGGTT-39.
Histology
For a representative subset of mice, left lung lobes were fixed in 10% neutral
buffered formalin (4˚C, 12 h) and then transferred to 70% ethanol and
processed to sections by SuRF@QMRI (The University of Edinburgh).
Samples were inserted into tissue tek cassettes, dehydrated, and embedded
in paraffin wax using a LEICA ASP processor and sectioned. Sections
were baked for 12 h at 55˚C, followed by dewaxing in xylene and rehy-
FIGURE 2. Exposure to LL-37 reduces RSV N- and F-protein colocalization. RSV, treated with endotoxin-free water (as vehicle control; A), 25 mg/ml
LL-37 (B), or 25 mg/ml scrLL-37 (C), was immediately air-dried on glass slides, fixed, and permeabilized, before incubation with anti-RSV F- and
N-protein Abs, followed by labeled secondary Abs and assessment by confocal microscopy. (A–C) Images show representative regions (original magni-
fication 3100) demonstrating F-protein (F AF488; green), N-protein (N AF594; red), overlay of channels, and completely colocalizing particles as de-
termined by the IMARIS. The volume of fully colocalized signal quantified using IMARIS (D) and the number of double-positive particles counted using
ImageJ (E) is displayed as a percentage, relative to untreated virus. Data represent mean6 SEM for n = 3 independent experiments, performed in duplicate,
assessing at least 10 random fields per condition (100–500 particles per field of view), analyzed by one-way ANOVAwith Dunnett posttest (*p, 0.05, **p, 0.01,
***p , 0.001).
FIGURE 3. Exposure to LL-37
induces damage to RSV membrane
integrity. Cryotransmission electron
micrographs of control RSV (A) and
RSV exposed to 25 mg/ml LL-37,
followed by immediate vitrification
(B). Micrographs were taken at a
nominal original magnification
350,000 and underwent visual in-
spection using ImageJ. Micrographs
represent observations from at least
two independent experiments, with a
minimum of two grids analyzed per
condition. Black arrowhead indicates
intact membrane; white arrowhead in-
dicates membrane damage; and black
arrow indicates free capsid material.
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dration using descending concentrations of ethanol baths (100 to 70%).
Sections were stained with hematoxylin (5 min; Sigma-Aldrich), washed,
and differentiated in 1% acid alcohol, before slides were transferred to
Scott’s tap water substitute (Sigma-Aldrich) and transferred to eosin so-
lution (2 min; Thermo Fisher Scientific). Slides were washed, dehydrated,
and cleared using rising concentrations of ethanol baths (70–100%) and
xylene. Lung sections were assessed for severity of inflammation, blinded
to genotype and treatment.
Experimental RSV infection of human adults
A cohort of healthy nonsmoking adults (aged 18–33 y; with no underlying
immunodeficiencies) was enrolled, and infection studies were conducted as
previously described (18). In brief, nasal lavage (collected by instilling
0.9% saline using a 10-ml syringe with attached metal nasal olive [Clinical
Engineering, Royal Brompton Hospital, London, U.K.] and washing the
nose 10 times over a 1-min period) and blood samples were collected
immediately before inoculation with 104 PFU RSV A Memphis 37 [M37
(Meridian Lifesciences, Memphis, TN); a low-passage virulent strain of
RSV that was produced according to Good Manufacturing Practice) by
intranasal drops. Bronchoalveolar lavage was obtained 2 wk before inoc-
ulation. Subjects were subsequently housed in residential quarantine for
10 d. Infection was defined by detection of RSV nucleoprotein gene by
Q-RT-PCR in nasal lavage on at least 2 d between days 2 and 10 postin-
oculation. Samples were stored at 280˚C and quantified for hCAP-18/LL-
37 by ELISA (HK321-02; Hycult Biotech, Uden, the Netherlands)
according to manufacturer’s instructions, using samples as collected
(i.e., not concentrating the lung and nasal washes). Study remained blinded
until completion.
Statistical analysis
Statistical analysis was performed using the GraphPad PRISM5 statistical
package (GraphPad Software, La Jolla, CA) and Minitab 16 statistical
software (Minitab, Coventry, U.K.) by Student t test, one-way ANOVAwith
Dunnett multiple comparison posttest, two-way ANOVA with Bonferroni
posttest, or general linear model ANOVA as stated in the respective figure
legends. The p values ,0.05 were considered significant.
Results
LL-37 binds directly to RSV virions
To determine whether LL-37 directly interacts with RSV, we
assessed peptide binding to virion particles by ELISA. To guarantee
specificity of the assay, we tested binding in both directions. Wells
coated with LL-37 (or BSA, or scrLL-37 as controls) were incu-
bated with RSV, followed by detection of binding with anti-RSVAb
(Fig. 1A). RSV had a significantly higher binding affinity to LL-37
than to BSA or to scrLL-37. Wells coated with RSV (or, as
binding controls, coated with either BSA or medium derived from
uninfected cells) were incubated with LL-37 peptide, followed by
detection of binding using anti–LL-37 Ab (Fig. 1B). LL-37
showed significantly greater binding to RSV than to BSA con-
trol. In contrast, LL-37 binding to tissue culture medium–coated
wells was equivalent to BSA-coated wells. These data demon-
strate that LL-37 directly binds RSV virion particles.
LL-37 disrupts the RSV viral membrane
The functional conformation of viral envelope-bound proteins,
including attachment- and fusion-proteins, is preserved by the
integrity of the viral envelope (19). Changes in its structural in-
tegrity can lead to altered protein folding, causing loss of function.
To investigate whether LL-37 binding of RSV caused destabili-
zation of viral particles, we examined immunofluorescent coloc-
alization of the RSV fusion protein (F-protein; which is bound on
the viral envelope) and N-protein (found in the capsid), as pre-
viously described (16). Confocal microscopic assessment of un-
treated, purified RSV samples for F- and N-protein revealed three
distinct populations (Fig. 2A): intact viral particles (colocalization
of F-and N-proteins), capsid-free virus-like particles (F-protein
only), and free capsid material (N-protein only). Changes in
the proportions of each population after treatment with LL-37
(Fig. 2B) or scrLL-37 (Fig. 2C) were then quantified (Fig. 2D, 2E)
by IMARIS. RSV exposed to LL-37 demonstrated a significantly
lower overall level of colocalization of the F- and N-proteins
(representing partial and/or complete viral particle disruption)
than controls and scrLL-37–treated virus (Fig. 2D). Furthermore,
there was significantly more complete particle disruption (dem-
onstrated by single signal-positive particles) and a corresponding
decrease in the number of particles with any degree of colo-
calized F- and N-signals (Fig. 2E). These data demonstrate
FIGURE 4. LL-37 exposure results in lower level of RSV binding to
HEp-2 cells. HEp-2 cells were infected with RSV (MOI = 1) at 4˚C (A and
B) or 37˚C (C), delivered concomitantly with 25 mg/ml LL-37, 25 mg/ml
scrLL-37, or carrier control, for 1 (A and B) or 2 h (C). Cells were then
either fixed, labeled with anti-RSV F-protein Ab and corresponding sec-
ondary Ab and analyzed by flow cytometry (A), protein collected and
examined by Western immunoblot for F-protein and b-actin, as a loading
control (B), or washed and incubated for a further 24 h before collection of
total cell RNA for TaqMan-based Q-RT-PCR (C). (A) Mean fluorescence
intensity (MFI) normalized to control infected cells for n = 3 independent
experiments, performed in duplicate and analyzed by one-way ANOVA
with Dunnett posttest (***p , 0.001). (B) Western blot for F-protein in
total infected HEp-2 cell protein, representative of n = 3 independent
experiments. (C) Transcription of IFN-b, IL-28, and IL-29 in RSV-infected
cells treated concomitantly with LL-37, as a percentage of the matched
RSV-infected cells treated concomitantly with scrLL-37, showing mean 6
SEM for n = 3 independent experiments, performed in duplicate.
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LL-37–mediated separation of envelope- and capsid-based viral
proteins.
To visualize the impact of LL-37 on RSV viral membrane, we
assessed envelope integrity by transmission electron cryomicro-
scopy after exposure to LL-37 (Fig. 3) and vitrification, which
preserves the physiological state of envelope structures (20).
Untreated, purified RSV virions, with a range of shapes and sizes,
showed continuous envelope lining with the capsid contained
within the virus, in keeping with previous observations (21). In
contrast, in LL-37–exposed RSV samples, more particles with
obviously disrupted envelopes and free capsid content were ob-
served. Taken together, these data demonstrate a direct interaction
between LL-37 and RSV, resulting in breakdown of envelope in-
tegrity and viral particle disruption.
LL-37 inhibits epithelial cell binding of RSV and responses to
infection
Damage to the integrity of the RSVenvelope could result in loss of
function of envelope-bound attachment- and fusion-proteins, and
thus impaired cellular binding (19). HEp-2 epithelial cells and
reagents were cooled to 4˚C to inhibit the active fusion process of
RSV with epithelial cell membranes, while still permitting viral
binding (22), and then exposed to RSV for 1 h at 4˚C with con-
comitant exposure to LL-37, scrLL-37, or carrier only control.
Viral binding was assessed by flow cytometric analysis of epi-
thelial F-protein (Fig. 4A) and by F-protein Western blot of total
protein collected (Fig. 4B). LL-37, given concomitantly with RSV
infection, resulted in significantly lower levels of association of
F-protein, and thus RSV, with HEp-2 cells, relative to the scrLL-
37-treated and control infected cells. The scrambled control
peptide had no effect on binding, in either assay.
To then assess the impact of LL-37 on the epithelial cell response
to RSV infection at 37˚C, we examined the transcription of type I
and III IFN genes 24 h postinfection with concomitant adminis-
tration of LL-37, or scrLL-37 control. Transcription of IFN-b, IL-
28, and IL-29 was induced by RSV infection in all samples but
was significantly lower in LL-37–treated cells (Fig. 4C). Taken
together, these results are compatible with the notion that exposure
of RSV to LL-37, but not scrLL-37, at the time of infection results
in damage to viral particles, decreased binding to epithelial cells,
decreased infectivity, and subsequently, a lesser cellular response
to the virus.
LL-37 is protective against RSV infection in mice in vivo
Having demonstrated that LL-37 had antiviral properties against
RSV in vitro, the question whether these properties were functional
in vivo was addressed. A well-characterized model of murine
pulmonary RSV infection was used (23), following progress of
disease over 6 d after intranasal inoculation with RSV. Groups of
four littermates were separated into infection and control caged
pairs, with one mouse in each pair receiving LL-37 and the other
receiving scrLL-37 intranasally, concomitant with RSV or carrier
control. Mice were subsequently treated with daily intranasal in-
oculation of either LL-37 or scrLL-37. Weight loss was assessed
daily, pulmonary transcription of Ifn-b was assessed on day 1, and
viral load was determined on days 4 and 7.
RSV-infected mice treated with scrLL-37showed an early weight
reduction on day 1 postinfection, and a later period of weight loss
between days 4 and 6 (Fig. 5A), compatible with the established
model for untreated, RSV-infected mice (24). In contrast, RSV-
infected mice treated with LL-37 had significantly less weight loss
over the entire course of the experiment, when compared with
FIGURE 5. LL-37 is protective against RSV infection in vivo. Six- to eight-week-old female BALB/c mice in groups of four littermates were housed in
infected and uninfected sister pair cages and intranasally inoculated with 3–6 3 105 PFU RSVor PBS, concomitant with 10 mg LL-37 (given as 100 ml of
100 mg/ml solution) or scrLL-37 on day 0. On days 1–6, all mice received further inoculations of LL-37 or scrLL-37 intranasally, and weight was monitored
and assessed as a percentage of starting weight. (A–D) Data represent n = 9 animals per group, performed in three independent experimental blocks, shown
as mean 6 SEM, analyzed by (A) general linear model ANOVA (***p , 0.001, *p , 0.05) and (B–D) Wilcoxon matched-pairs signed rank test (**p ,
0.01, *p , 0.05). (E) Pulmonary RSV L-gene transcription was assessed at 4 and 7 d postinfection and expressed as fold change relative to the mean value
for scrLL-37–treated infected mice at virus peak on day 4. Data show mean 6 SEM from n = 6 mice/condition, analyzed by two-way ANOVA with
Bonferroni posttest (***p, 0.0001). (F) Pulmonary Ifn-b expression was assessed on day 1 postinfection and expressed as fold change relative to the mean
value for scrLL-37–treated uninfected. Data show mean 6 SEM from n = 6 mice/condition, analyzed by two-way ANOVAwith Bonferroni posttest (***p ,
0.001).
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scrLL-37–treated infected controls (Fig. 5B), showing a lesser
early weight loss (Fig. 5C) and no later weight loss (Fig. 5D),
being indistinguishable from uninfected controls from day 3 on-
ward (Fig. 5A). Using a general linearized model (to assess the
efficacy of LL-37 against infection, relative to any impact of
peptide treatment alone), we compared the difference in weight
loss between matched infected and uninfected littermates given
LL-37 with the difference between their infected and uninfected
littermates given scrLL-37, and this was found to be significant at
both the early (p, 0.05) and the later (p, 0.01) phases of weight
loss, and for total weight loss over the whole study (p , 0.001).
Analysis of RSV L-gene transcription in the lung (Fig. 5E) showed
a significant, 60% lower viral load in the LL-37–treated mice
compared with the scrLL-37–treated animals at day 4 (the time
point of peak viral load in this model) (25). No difference between
LL-37– and scrLL-37–treated mice was observed by day 7, by
which time the virus has largely been cleared in this model. These
data could be compatible with rapid early antiviral activity of LL-
37 directly reducing the effective infective load of virus, LL-37
treatment promoting enhanced clearance of RSV, or LL-37 pre-
venting spread of infection. To examine the magnitude of early
host response to initial viral load and infection, we evaluated Ifn-b
transcription at day 1 (Fig. 5F). Uninfected animals, treated daily
with LL-37 or scrLL-37, did not show any substantial expression
of Ifn-b. In contrast, control infected mice, treated with scrLL-37,
had a large, significant induction of Ifn-b expression in response to
virus. However, infected mice treated with LL-37 had significantly
lower levels of Ifn-b expression than control infected animals,
compatible with lower initial infectious load. These data support a
rapid, early impact on RSV infectivity, resulting in protection
against disease.
Prophylactic or therapeutic intranasal delivery of LL-37 in
murine RSV infection
The exposure of epithelial cells to LL-37 before RSV infection
resulted in reduced viral infection in vitro (7). In addition, LL-37
treatment applied after initiation of RSV infection prevented the
spread of infection in vitro (7). Therefore, in vivo studies were
conducted to determine whether the protective properties dem-
onstrated with concomitant application of LL-37 could be ex-
tended to prophylactic and/or therapeutic potential against RSV
infection in vivo. Groups of four littermate mice were intranasally
inoculated with LL-37 either 1 h before, 1 h after, or concomi-
tantly with RSV infection, or with concomitant scrLL-37 appli-
cation, and subsequently treated with continued daily intranasal
inoculation with either LL-37 or scrLL-37 as appropriate. In
contrast with the significant protective effects of concomitant LL-
37 delivery, neither pretreatment nor delayed initial application of
LL-37 had protective effects on weight loss over the entire course
of the infection (Fig. 6A), nor did these approaches alter viral load
at 4 d postinfection (Fig. 6B). However, application of LL-37 at
1 h before virus did result in significantly less weight loss in the
first 24 h postinfection, comparable with that of concomitant de-
livery of LL-37. These data suggest that effective pulmonary
colocalization of RSV and LL-37 may be critical for immediate
direct antiviral activity.
mCRAMP has antiviral activity against RSV in vitro and is
induced by RSV in vivo
Mice, like humans, express one sole cathelicidin (13). The murine
ortholog of hCAP-18/LL-37 is mCRAMP, expressed by the Camp
gene. To investigate whether mCRAMP also has antiviral activity
against RSV, we infected HEp-2 cells in the presence or absence
of mCRAMP over a range of concentrations. Concomitant ap-
plication of the murine peptide mCRAMP was found to have a
similar, concentration-dependent antiviral activity on RSV in this
in vitro assay (Fig. 7A), but to be less potent than the human
peptide LL-37. Having established that mCRAMP had anti-RSV
activity in vitro, the extent to which the peptide was expressed in
the murine lung in vivo was determined in uninfected mice and on
day 1 postinfection with RSV, both in the presence and the ab-
sence of concomitant LL-37 treatment. The proform of mCRAMP,
but not the cleaved active peptide, was detected by Western blot at
low levels in the uninfected lung (Fig. 7B–D). Treatment with LL-
37 or scrLL-37 alone had no significant effect on mCRAMP ex-
pression. However, at 1 d after RSV infection, Camp transcription
(Fig. 7E) and mCRAMP peptide levels (Fig. 7C, 7D) were both
significantly upregulated, and the active cleaved form was now
detected (Fig. 7B). The quantity of cleaved mCRAMP detected
was significantly greater in the control infected mice than the LL-
37–treated infected animals (Fig. 7D), compatible with a larger
effective infectious stimulus. These data suggest that endogenous
FIGURE 6. Prophylactic or therapeutic LL-37 administration in RSV
infection. Six- to eight-week-old female BALB/c mice in groups of four
cohoused littermates were intranasally inoculated on day 0 with 3–6 3 105
PFU RSV and 10 mg LL-37 (given as 100 ml of 100 mg/ml solution),
applied intranasally either 1 h before, 1 h after, or concomitantly with
infection, or with concomitant delivery of scrLL-37. On days 1–6, all mice
received further inoculations of LL-37 or scrLL-37 as appropriate, and
weight was monitored and assessed as a percentage of starting weight. (A)
Data represent n = 8 animals per group, performed in three independent
experimental blocks, shown as mean 6 SEM, analyzed by one-way
ANOVAwith Dunnett posttests, *p, 0.05 (comparing concomitant LL-37
with control infected), cp , 0.05 (comparing LL-37 pretreatment with
control infected). (B) Pulmonary RSV L-gene transcription was assessed at
4 d postinfection and expressed as fold change relative to the mean value
for scrLL-37–treated infected mice. Data show mean6 SEM from n = 4–6
mice/condition, analyzed by one-way ANOVA with Dunnett posttests
(*p , 0.05).
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cathelicidin could also play an antiviral role against RSV infection
in the murine lung.
Endogenous mCRAMP is protective in RSV infection in vivo
Having established that mCRAMP has anti-RSV potential and is
induced by RSV infection, the significance of this peptide was
evaluated in Camp2/2 mice, using the intranasal RSV infection
model. Littermate pairs were separated into infected and unin-
fected cages, cohousing wild-type and Camp2/2 mice in each
cage, studied in a series of experimental blocks. Mice were in-
oculated on day 0 with RSV, or PBS as a carrier control. Weight
loss was monitored for 6 d, viral load was assessed at day 3, and
lung histology was examined at day 6. Uninfected mice of both
genotypes gained weight over the course of the experiment
(Fig. 8A). RSV-infected mice had two phases of weight loss, as
described earlier, with the Camp2/2 mice losing significantly
more weight over the course of the study (Fig. 8A, 8B). In contrast
with the effects of concomitant LL-37 inoculation, deletion of the
Camp gene had no significant effect on weight loss over the first
24 h (Fig. 8C). This is a period in which the active, cleaved form
of mCRAMP was not present in either genotype (Fig. 7B–D), but
induction of Camp was initiated in wild type controls (Fig. 7E).
However, weight loss in the second phase (days 4–6) was sig-
nificantly greater in the Camp2/2 mice, with these animals losing
almost twice as much weight over that period than the paired wild-
type controls (Fig. 8D), and by the end of the study, Camp2/2
mice had more extensive inflammatory infiltrates in the lungs
(Fig. 8E). This increased disease severity was accompanied by a
greater viral load (assessed by L-gene expression) in the Camp2/2
mice at day 3 postinfection (Fig. 8F), compared with matched
wild type controls. These data demonstrate that endogenous pro-
duction of mCRAMP during RSV infection has a nonredundant
role in limiting disease severity.
Susceptibility to human experimental RSV infection is
associated with lower basal LL-37 levels in nasal lavage
The observations that endogenous cathelicidin expression had
protective function against pulmonary RSV in mice in vivo, and
that immediate interaction with LL-37 diminished the infectivity of
RSV in vitro and in vivo, led to the hypothesis that higher con-
stitutive, upper airway hCAP-18/LL-37 expression at the primary
sites of infection with RSV may represent a protective barrier in
humans in vivo. To investigate this hypothesis, we collected nasal
lavage, bronchial lavage, and plasma samples from healthy adult
volunteers before undergoing experimental challenge with RSV
and assessed them for hCAP-18/LL-37 content, blinded to clinical
outcome. A proportion of individuals, inoculated with RSV A
Memphis 37 by intranasal drops, subsequently developed upper
respiratory tract infection, based on detection of RSV by Q-RT-PCR
in nasal lavage on at least 2 d between days 2 and 10 after inocu-
lation. RSV-uninfected individuals were found to have had signifi-
cantly greater levels of hCAP-18/LL-37 in their nasal lavages at day
0 (before RSV inoculation) than RSV-infected individuals (Fig. 9A).
These differences were not recapitulated in bronchoalveolar lavage
FIGURE 7. Murine cathelicidin is antiviral against RSV and induced by infection. (A) HEp-2 cells were infected with RSV administered concomitantly
with a concentration range of mCRAMP (1, 10, 25, 50 mg/ml), 25 mg/ml LL-37, or carrier control for 2 h, washed, and incubated for 24 h in fresh medium.
Immunoplaque assay was used to quantify the number of infected cells relative to the infected carrier control. Data show mean 6 SEM for n = 3 in-
dependent experiments, performed in triplicate, analyzed by one-way ANOVAwith Dunnett multiple comparison posttest (**p , 0.01, ***p , 0.001). (B–
D) Wild type mice were intranasally inoculated with 3–6 3 105 PFU RSVor PBS, concomitant with 10 mg LL-37 (given as 100 ml of 100 mg/ml solution)
or scrLL-37, and culled 24 h later. Uninfected Camp2/2 mice were used as a negative control. Total protein and RNA were prepared from lung lobes and
assessed for mCRAMP and b-actin (as a loading control) by Western immunoblot (B) quantified by Li-Cor Odyssey (C and D), and assessed for Camp
expression by TaqMan-based Q-RT-PCR (E). Data show mean 6 SEM expression levels, relative to the mean level in scr-LL-37–treated uninfected
controls, from n = 6 per group, analyzed by two-way ANOVA with Bonferroni posttest (*p , 0.05, ***p , 0.0001). n.d., not detected.
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samples (Fig. 9B), nor were any significant differences observed
in plasma cathelicidin levels (Fig. 9C). These data suggest that
low constitutive nasal expression of hCAP-18/LL-37 at the point
of contact with RSV may be associated with an increased sus-
ceptibility to infection in humans.
Discussion
Infection with RSV is one of the most common causes of respi-
ratory tract illness in infants, especially in premature babies, al-
though it is also an important cause of morbidity and mortality in
elderly and immunocompromised individuals (26–29). By the age
of 2 y, almost every child has experienced RSV infection (30),
resulting in severe, life-threatening disease in ∼2% of infants (2).
National Health Service England recorded 5938 RSV-associated
hospital admissions of infants in 2012–2013 (31), whereas glob-
ally, RSV infection results in an estimated 200,000 deaths in
young children annually (3), with 3.4 million infants requiring
hospitalization. Furthermore, studies suggest a correlation be-
tween RSV-triggered bronchiolitis and the risk for long-term
health issues including recurrent wheezing, asthma, and allergic
sensitization (4, 5, 32). Despite this, there are no effective, specific
therapeutic interventions or vaccine.
In this study, we demonstrate that human and murine cath-
elicidins, widely expressed host defense peptides, have direct
antiviral effects on RSV in vitro, have protective effects against
RSV infection in vivo in murine models, and are associated with
protection against RSV infection in adult humans. Cathelicidins
have a broad spectrum of functions, both directly antibacterial and
modulatory. The human cathelicidin LL-37 has been shown to
promote bacterial clearance in murine pulmonary infection models
(33, 34), and Camp2/2 mice have increased susceptibility to
bacterial infection in a wide range of organs, including skin (17),
intestinal tract (35), urinary tract (36), cornea (37), and lung (34,
38), demonstrating the critical, nonredundant role for cathelicidin
in murine host defense against bacterial infection. However, in
addition to their antibacterial functions, some host defense pep-
tides have also been shown to have various antiviral properties
in vitro (39), an observation that we and others have recently
extended to cathelicidins (7, 40, 41). However, the relative im-
portance of directly microbicidal properties versus modulatory
functions in the protective in vivo effects of these peptides against
bacterial and viral infections remains to be determined.
The modulatory properties of cathelicidins include the capacity
to modify pattern recognition receptor signaling, and, with specific
relevance to viral infections, LL-37 has been shown to enhance
viral dsRNA signaling via TLR3, promote cytokine responses in
rhinovirus-infected human airway epithelial cells (42), and aug-
ment IFN-b responses of human keratinocytes upon stimulation
with polyinosinic-polycytidylic acid (43). TLR3- and RIG-I–me-
diated type I IFN responses constitute a critical component of the
antiviral host response to RSV (44), generating the hypothesis that
the antiviral effects of LL-37 against RSV may be mediated via an
upregulation of this system. However, our data demonstrated the
opposite effect, with LL-37 coadministration leading to signifi-
FIGURE 8. Endogenous mCRAMP is protective against RSV infection in vivo. Eight- to twelve-week-old female littermate pairs of Camp2/2 or wild-
type (wt) C57BL/6J OlaHsd mice were split between infected and matched uninfected cages, cohousing both genotypes. Mice were infected with 3–63 105
PFU RSV. Weight was monitored and assessed as a percentage of starting weight. (A–D) Data represent n = 6 animals per group, performed in three
independent experimental blocks, shown as mean 6 SEM, analyzed by Wilcoxon matched-pairs signed rank test, comparing genotypes (*p , 0.01). (E)
Light micrographic images of pulmonary histology of H&E-stained lungs collected at day 6 postinfection, shown at original magnification 3100, rep-
resentative of n = 3 per genotype. (F) Pulmonary RSV L-gene transcription was assessed at 3 d postinfection and expressed as fold change relative to the
mean value for wt infected mice. Data show mean 6 SEM from n = 8 mice per condition, analyzed by Wilcoxon matched-pairs signed rank test.
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cantly lower production of type I and type III IFNs by HEp-2 cells
in vitro. A recent study demonstrated that alveolar macrophages
are the key type I IFN-producing cells in murine RSV infection
in vivo (45), raising the possibility that this LL-37–mediated
modulation of this system could remain relevant in vivo. However,
our in vivo studies also demonstrated lower IFN-b induction by
RSV in the presence of LL-37. These observations, in conjunction
with our previous findings (7), confirm that the antiviral effects of
LL-37 are not mediated through modulation of IFN pathways.
Given the antiviral effects of cathelicidins, the lower levels of
IFNs are instead compatible with direct effects of LL-37 on RSV
lowering the effective infectious dose.
In vitro analysis of the interaction between LL-37 and RSV
demonstrated direct binding of the virus by the peptide, disruption
of viral particles, and decreased binding of RSV to epithelial cells
in vitro. These data all suggest that the primary antiviral mechanism
of the peptide in vitro resulted from direct activity on the viral
particle. This was confirmed in vivo, with concomitant delivery of
LL-37 required for maximally effective protection against disease
and lower viral loads in our murine model. Intranasal instillation of
LL-37 at 1 h before infection was equally effective at preventing
early-phase weight loss, proposed to be triggered by very high
initial viral load causing perivascular edema and damage of the
airway epithelium (24). This is compatible with the concept of
cathelicidin providing a first contact antiviral shield in the nose,
diminishing early viral load. The observation that this did not
result in effective longer-term protection against disease may re-
flect some loss of available LL-37 before infection, because of
uptake by epithelial cells (46), or lack of colocalization of the two
separate intranasal inocula, resulting in survival of a sufficient
proportion of RSV to cause later disease. A primary directly an-
tiviral mode of action for LL-37 is in keeping with the in vitro
antiviral mechanisms described for LL-37 on influenza (41) and
vaccinia virus (47) and human b-defensin 2 on RSV (19), for
which viral membrane disruption are described. However, to date,
evidence for significance of these antiviral properties of host de-
fense peptides in vivo is minimal.
Camp2/2 mice have been shown to develop significantly more
pox skin lesions than controls postinfection with vaccinia virus
(48), and we have previously demonstrated that inhaled LL-37 and
mCRAMP can protect against influenza as effectively as zana-
mivir (a neuraminidase inhibitor currently used in humans) in a
murine model (40). Our data now demonstrate that the intranasal
delivery of exogenous cathelicidin is protective against RSV in-
fection in vivo, but also, importantly, that Camp2/2 mice develop
significantly more severe disease than wild-type controls in re-
sponse to infection with RSV. These data highlight a nonredun-
dant role for cathelicidins in the natural host defense against this
respiratory pathogen. The early-phase response to RSV infection
was not affected in Camp2/2 mice, an observation likely to be
attributable to the low level of pulmonary expression of mCRAMP
and absence of the cleaved, active peptide at the time of infection.
This could represent an equivalent absence, in both genotypes, of
a first point of contact antiviral shield (enhanced by prior or
concomitant instillation of exogenous LL-37 in the other studies).
However, we demonstrate that RSV infection induced pulmonary
cathelicidin expression in wild type mice in vivo, compatible with
previous in vitro studies (49), and that Camp2/2 mice developed
significantly greater later-phase weight loss, viral load, and lung
inflammation. These data demonstrate the antiviral importance of
endogenous cathelicidin expression. However, a role for modu-
latory properties of this peptide protecting against systemic dis-
ease cannot be excluded, irrespective of early virucidal properties.
Although cathelicidin treatments significantly enhanced survival
rates, and resulted in less weight loss and lower levels of in-
flammatory lung cytokines in influenza-infected mice, relatively
minor reductions in viral load were observed (40). In addition,
mice deficient in murine b-defensin 1 had significantly greater
weight loss and lethality when infected with influenza, despite
viral load being unaffected (50). Furthermore, we recently pro-
vided the first in vivo evidence of cathelicidin-mediated protection
against infection acting primarily via inflammomodulatory prop-
erties, in a Pseudomonas aeruginosa murine lung infection model
(34). Therefore, a detailed future examination of the impact of
cathelicidins on the inflammatory and immunological responses to
viruses, including to RSV, will be required to examine this pos-
sibility.
Our observations in Camp2/2 mice demonstrate the importance
of endogenous cathelicidin induced postinfection and, therefore,
contrast with the absence of any protective effect of intranasal
FIGURE 9. Higher nasal LL-37 levels are associated with protection in
an experimental human RSV infection model. Nasal lavage (A), bron-
choalveolar lavage fluid (B), and plasma (C) were collected from a cohort
of healthy, nonsmoking adults (age 18–33 y), before intranasal inoculation
with 104 PFU RSV A Memphis 37. Individuals were monitored and cat-
egorized as RSV infected or RSV uninfected based on detection of nasal
RSV by Q-RT-PCR on at least 2 d between days 2 and 10 postinfection.
Nasal and plasma samples from 10 uninfected and 9 infected individuals,
and bronchoalveolar lavage fluid samples from 7 uninfected and 5 infected
individuals were quantified for LL-37/hCAP-18 levels by ELISA, in du-
plicate, in blinded fashion. Results are displayed as mean 6 SEM and
analyzed by t test, *p , 0.05.
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delivery of LL-37 given 1 h after RSV infection and daily there-
after. This may relate to inappropriate pulmonary localization
of exogenously delivered peptide, as opposed to localized endo-
genous production, differences between LL-37 and mCRAMP,
timing of deliveries, or localized extracellular or intracellular
peptide concentrations. Regardless, these data suggest that deliv-
ery of cathelicidin, or synthetic analogs, could have therapeutic
value in an established infection, if delivery and localization were
correctly optimized. Furthermore, the direct antiviral effects of
LL-37 in vitro and early-phase protection in vivo suggest the
possible potential of interventional strategies aimed at enhancing
this upper airways first point of contact antiviral shield. This ap-
proach is further supported by the observations from a human
RSV experimental infection model that higher levels of nasal
hCAP-18/LL-37 were associated with protection against RSV
infection. It is important to recognize that this study evaluated
infection in healthy adults, in whom RSV is not a clinical problem,
and found that other mechanisms, such as IgA memory, are of
significance to outcome in these cohorts (18). However, these data
raise the possibility that baseline levels of cathelicidin in the upper
respiratory tract may be of much greater significance in young
infants with a first RSV infection, in whom adaptive immunity will
not have the same significance in determining the outcome of
infection. In that regard it will be important to study the factors
that determine variations in baseline expression levels of cath-
elicidins.
Expression of cathelicidin in humans is regulated by vitamin D
(51) and can be further enhanced by exposure to RSV in the
presence of vitamin D (49). This raises the possibility that lower
levels of vitamin D may impair cathelicidin-mediated defense
against RSV. Lower serum 25(OH) vitamin D3 levels observed
in winter are associated with increased risk for respiratory in-
fections (52, 53), and newborns with low cord blood 25(OH)
vitamin D3 levels have a significantly greater risk for subsequent
RSV-associated lower respiratory tract infections (54). Median
serum levels of hCAP-18/LL-37 in children with RSV bron-
chiolitis were found to be significantly lower than in those with
human rhinovirus-induced bronchiolitis (55). Furthermore, RSV-
infected children with hCAP-18/LL-37 levels lower than the
median had more severe disease than those with hCAP-18/LL-37
levels above the median (55). In combination with our findings,
these studies highlight the anti-RSV potential for therapeutic or
preventative strategies that boost cathelicidin expression. The
development of approaches for hCAP-18/LL-37 induction cur-
rently includes evaluation of the drug 4-phenylbutyrate, shown
to upregulate cathelicidin with therapeutic potential in animal
models (56–58) and/or the use of vitamin D supplementation,
which should be considered as a novel preventative strategy
against RSV infection, particularly in winter in the northern
hemisphere.
Thus, our new data lead us to propose that cathelicidins are a key,
nonredundant component of host defense against airway infection
with RSV, functioning as a first point of contact antiviral shield,
acting via peptide-mediated disruption of viral particles in the
upper airways, and having additional later-phase roles in mini-
mizing the severity of disease outcome. Consequently, cathelicidins
represent an inducible target for preventative strategies against
RSV infection and may inform the design of novel therapeutic
analogs for use in established infection.
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